06:41:46 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Beskrivning

LandSverige
ListaMid Cap Stockholm
SektorHÀlsovÄrd
IndustriMedicinteknik
Bonesupport Àr verksamma inom medicinteknik. Bolaget utvecklar och kommersialiserar injicerbara biokeramiska bengraftsubstitut som ombildas till patientens eget ben och har förmÄga att frisÀtta lÀkemedel. Bolagets bengraftsubstitut Àr baserade pÄ teknologiplattformen Cerament. I dagslÀget genomför bolaget löpande kliniska studier. Bolaget innehar försÀljning i Europa och Nordamerika och huvudkontoret ligger i Lund.

Kalender

2022-10-27 Kvartalsrapport 2022-Q3
2022-07-14 Kvartalsrapport 2022-Q2
2022-05-20 Ordinarie utdelning BONEX 0.00 SEK
2022-05-19 ÅrsstĂ€mma 2022
2022-05-04 Kvartalsrapport 2022-Q1
2022-02-17 Bokslutskommuniké 2021
2021-11-04 Kvartalsrapport 2021-Q3
2021-07-15 Kvartalsrapport 2021-Q2
2021-05-21 Ordinarie utdelning BONEX 0.00 SEK
2021-05-20 ÅrsstĂ€mma 2021
2021-05-06 Kvartalsrapport 2021-Q1
2021-02-17 Bokslutskommuniké 2020
2020-11-05 Kvartalsrapport 2020-Q3
2020-07-17 Kvartalsrapport 2020-Q2
2020-05-20 Ordinarie utdelning BONEX 0.00 SEK
2020-05-19 ÅrsstĂ€mma 2020
2020-05-08 Kvartalsrapport 2020-Q1
2020-02-26 Bokslutskommuniké 2019
2019-11-07 Kvartalsrapport 2019-Q3
2019-07-25 Kvartalsrapport 2019-Q2
2019-05-15 Ordinarie utdelning BONEX 0.00 SEK
2019-05-14 ÅrsstĂ€mma 2019
2019-05-02 Kvartalsrapport 2019-Q1
2019-02-27 Bokslutskommuniké 2018
2018-11-07 Kvartalsrapport 2018-Q3
2018-07-26 Kvartalsrapport 2018-Q2
2018-05-23 Ordinarie utdelning BONEX 0.00 SEK
2018-05-22 ÅrsstĂ€mma 2018
2018-05-04 Kvartalsrapport 2018-Q1
2018-02-20 Bokslutskommuniké 2017
2017-11-02 Kvartalsrapport 2017-Q3
2017-08-17 Kvartalsrapport 2017-Q2
2022-05-04 08:00:00

BONESUPPORT Holding AB (publ), a leading company in orthobiologics for the management of bone injuries, today publishes the interim report for the first quarter 2022.

STRONG SALES GROWTH


JANUARY – MARCH 2022

  • Net sales increased by 48 percent (36 percent at constant exchange rates) and amounted to SEK 66.3 million (44.8).
  • The North America (NA) segment reported a sales increase of 64 percent (47 percent at constant exchange rate).
  • The Europe & Rest of the World (EUROW) segment reported a sales increase of 28 percent (22 percent at constant exchange rates).
  • The gross margin amounted to 90.5 percent (88.6) with a positive mix effect from increased sales in North America.
  • Operating result amounted to SEK -16.5 million (-19.7).
  • Earnings per share, before and after dilution, were SEK -0.25 (-0.32).

"U.S. sales grew with 64 percent in the quarter." Emil BillbÀck, CEO


EVENTS DURING THE REPORTING PERIOD

  • In January 2022, the company announced that a distribution agreement had been signed with OrthoPediatrics Corp, a leading company in the orthopedic pediatric market. The distribution partnership expands BONESUPPORT’s market access further as it gives CERAMENT BVF access to OrthoPediatrics’ network of 250 children’s hospitals. Sales for the period included a first order from OrthoPediatrics, which amounted to SEK 2.6 million.

EVENTS AFTER THE REPORTING PERIOD

  • CMS, Centers for Medicare & Medicaid Services, communicated in end of April a favorable NTAP, New Technology Add-On Payments, ruling for CERAMENT G at USD 4 920, conditioned a regulatory approval before July 1 this year.